The dogs were rescued from a facility where one million dogs were killed over 25 years. Source: Four Paws
Carolyn Everson — vice president of Facebook's Global Business Group — responded to criticism over the spread of vaccine misinformation on the platform, saying the company is "taking very aggressive measures" to remove such content.
Spotify may reportedly launch paid podcast subscriptions next week, offering an answer to Apple's just-launched feature.
The tunnel boring machine market in North America is expected to grow from US$ 1,448. 63 million in 2019 to US$ 2,106. 47 million by 2027; it is estimated to grow at a CAGR of 5. 2% from 2020 to 2027.New York, April 23, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "North America Tunnel Boring Machine Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type, Geology, and End-User" - https://www.reportlinker.com/p06065028/?utm_source=GNW Tunnel boring machines usually have diameters from 5–17 meters.Microtunnel boring machines are smaller, with an excavation diameter of ~4 meters.At present, microtunnel activities are widely used to construct several kilometers of underground infrastructure.It is considered as a fast alternative to traditional pipe installation systems.It is an automated process of boring and pipe installation used for excavation utility facilities such as wastewater, freshwater, oil & gas, communications, and electricity.Use of these machines is rising since they create less environmental impact compared to conventional excavation methods.Microtunnels have grown in North America to replace aging infrastructure in the US. The requirement for enhanced infrastructure across North America is robust and stronger as the existing utility systems are aging. Thus, the region is highly focused on investing in microtunneling projects to meet the growing requirements of infrastructure. Also, increasing infrastructure projects related to roads is among the factors bolstering the demand for tunnel boring machines in North America.In terms of end-user, the transportation segment led the North America tunnel boring machine market in 2019.As the population is increasing and the countries across North America demand for more transportation services, the requirement for tunnels is also growing.The tunnel boring machine is highly used for road and railway transportation.The growing metropolitan rail infrastructure and increasing government investments in pipelines, railways, and road infrastructure across North America are propelling the market growth.Major countries are focused on deploying tunnel boring machines for urban transportation. For instance, in Seattle, Washington, the US, the world’s largest tunnel boring machine—namely, Fat Bertha—dug a highway tunnel, which was ~18 meters in height, weighed 70 tonnes, ~100 meters long, and 17.5 meters in diameter. Thus, the mounting investments in the construction industry for urban transportation, along with the growing penetration of tunnel boring machines, would spur the market growth during the forecast period.North America is severely affected by the COVID-19 pandemic.North America, particularly the US, witnessed an unprecedented rise in the number of confirmed cases resulting in large-scale lockdown across different regions and industrial activities.It is one of the most important regions for the adoption and growth of new technologies due to favorable government policies to boost innovation, a huge industrial base, and the high adoption of automation in various industries, especially in developed countries such as the US and Canada.Hence, any hindrance on the growth of industries adversely affects the economic growth of the region.In January 2021, due to a pandemic, restrictions were imposed by British Columbia, Canada.Thus, it disrupted work at construction locations of a Rio Tinto hydropower project and BC Hydro’s Site C dam.The project is likely to resume operations after receiving an approval to surge the number of onsite workers to safely operate the tunnel boring machine. Moreover, the component manufacturer, supply chain, and distributor’s lack of availability have significantly disrupted the production of tunnel boring machines. Thus, the market witnessed a drop in the demand from the end-users in 2020 and it is likely to recover from the impact of the COVID-19 pandemic in mid-2021.The overall North America tunnel boring machine market size has been derived using both primary and secondary sources.To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the market.The process also serves the purpose of obtaining an overview and forecast for the North America tunnel boring machine market with respect to all the segments pertaining to the region.Also, multiple primary interviews have been conducted with industry participants and commentators to validate the data, as well as to gain more analytical insights into the topic.The participants of this process include industry experts such as VPs, business development managers, market intelligence managers, and national sales managers, along with external consultants such as valuation experts, research analysts, and key opinion leaders, specializing in the North America tunnel boring machine market. Dalian Huarui Heavy Industry Group Co., Ltd.; Herrenknecht AG; Hitachi Zosen corporation; IHI Corporation; Kawasaki Heavy Industries, Ltd.; Komatsu Ltd.; TERRATEC Ltd.; and The Robbins Company are among the players operating in the market.Read the full report: https://www.reportlinker.com/p06065028/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
The "Global Email Security Market, Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced additional data at a late-breaking session at the American Academy of Dermatology VMX Experience. Etrasimod, a novel investigational drug candidate to treat moderate-to-severe atopic dermatitis (AD), demonstrated statistical significance in both clinician and patient reported outcomes in the etrasimod 2 mg treatment group of Arena’s ADVISE Phase 2b clinical trial. Etrasimod is a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator. Topline results from the ADVISE Phase 2b clinical trial were announced in November 2020. Today’s results were presented by Emma Guttman-Yassky, MD, PhD, Waldman Professor and Chairwoman, The Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai.
(Bloomberg) -- Russia said it began pulling thousands of troops back from areas near the Ukrainian border Friday, in a move that could ease tensions that have spiked in recent weeks.The Defense Ministry released video on Twitter it said showed the troops returning to their bases and the Black Sea Fleet later reported that its ships had also been redeployed. Ukrainian President Volodymyr Zelenskiy welcomed Russia’s announcement of the move Thursday. U.S. officials, who have repeatedly called on Russia to remove the troops, said they were waiting for confirmation the pullback takes place.The ruble rose beyond 75 per dollar early Friday, the highest level since March, continuing a rally that began when Russia announced the planned pullback, easing fears the tensions could lead to new sanctions.Russia’s deployment of more than 100,000 troops, as well as tanks, warplanes and warships, to Crimea and other areas near the Ukrainian border over the last month had raised fears the Kremlin might be planning another attack on its neighbor. For weeks, Moscow rejected calls from Kyiv and its western allies to de-escalate, driving tensions to the highest levels in years. Russia said the troops were in the area for maneuvers.Concerns remain about how complete the action will be and whether tensions could flare again. Russia said the pullback will be completed by May 1 but it will leave the equipment, including tanks, of one of the units involved in the maneuvers in the area near the border ahead of training operations set for the fall.“If Russia really pulls back huge army forces from the border with Ukraine, it will ease tension. But this step doesn’t cease either escalation or the conflict,” Ukrainian Foreign Minister Dmytro Kuleba said Friday in comments on the ministry website.European Union spokeman Peter Stano said, “We will be watching closely the withdrawal of troops and the military equipment, which were amassed recently on Ukraine’s borders and in illegally-annexed Crimea.”The reaction in Western capitals was also cautious.“While the Russian troop pullout is a move in the right direction, yesterday’s announcement doesn’t change anything about the need to have an analysis of the causes that lead to this very tense situation and to identify measures for de-escalation in the future,” Romanian Foreign Minister Bogdan Aurescu said at a press conference Friday in Bucharest.Why Russia-Ukraine Tensions Are So Hard to Defuse: QuickTake“We’ll be looking for follow-through in terms of what the Russians actually do,” State Department spokesman Ned Price told reporters Thursday. Jen Psaki, the White House press secretary, said “We obviously want to de-escalate tensions not only in the relationship, but certainly at the border.”Amid the crisis, U.S. President Joe Biden called Putin to appeal to the Russian leader to reduce tensions, offering the prospect of a summit meeting later this year, a gesture the Kremlin welcomed.“Moscow thinks that it got its message across,” said Fyodor Lukyanov, head of the Council on Foreign and Defense Policy, which advises the Kremlin. “There’s been some de-escalation and now the confrontation has returned to the political and diplomatic sphere.”Russia denied its buildup was a threat to Ukraine but the Kremlin had charged the government in Kyiv with planning an assault on the Donbas. The Ukrainian government rejected those claims and accused Moscow of planning a military incursion of its own.(Updates with Ukrainian comment in 6th paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Insert "adjuvanted" before "COVID-19 vaccine" in first and fifth paragraphs.
Deputy Prime Minister Heng Swee Keat has “left behind big shoes to fill” at the Ministry of Finance (MOF), said Education Minister Lawrence Wong on Friday (23 April).
(Bloomberg) -- As lawmakers wrangle over President Joe Biden’s latest trillion-dollar stimulus package, currency investors are already picking the winners of the infrastructure spending boom that the plan is likely to unleash.They’re focusing on countries that are major sources of the copper needed to bolster the electrical grid, the iron ore for steel rebar, and nickel for battery-powered vehicles. For those who don’t typically invest directly in metals, foreign exchange is a prime way to express these views. The expectation is that certain commodity-linked currencies will get an extra jolt on top of the support from the broader reflation trade that’s dominated markets for months.With the president’s $2.25 trillion framework in mind, Tom Nakamura of AGF Management says he’s adding Canadian dollar exposure, while Jack McIntyre at Brandywine Global Investment Management is gaining confidence in his firm’s holdings of currencies such as Canada’s and Chile’s. Peter Azzinaro at Manulife Investment Management, meanwhile, who already likes the loonie and the Australian dollar, says he’s also starting to look at the Chilean peso.Biden’s proposal still faces steep challenges, and Republicans have countered with a much smaller offer. But early assessments are already forming in currencies, where investors are looking past the potential drag on growth from tax hikes in the plan. Instead, they’re focusing on its potential to bolster economies across much of the commodity-producing world, with Europe and Asia also eyeing infrastructure improvements.“Investors are not only banking on the global recovery trade, but they are also looking at a longer pipeline of infrastructure spending,” said Amarjit Sahota, a currency strategist and executive director of foreign-exchange services provider Klarity FX. “They’re getting more stubborn in holding those positions and aren’t letting go.”Of course, sussing out to what degree expectations for fresh infrastructure spending are driving markets is a challenge. Exchange rates depend on a dizzying, globe-spanning array of inputs -- including general risk sentiment, growth and interest-rate differentials, and these days, the relative success of vaccination campaigns.Futures EvidenceBut futures positions reflect the conviction behind the start of what’s known as a “supercycle” of demand for certain commodities, which could stretch over the next decade.Speculators that use leverage have unwound short futures positions on the Aussie since last year and have become less bearish on the loonie. Meanwhile, investors turned bullish on the Chilean peso as copper prices rose, data from that nation’s central bank show. Not all commodity currencies are benefiting, though: Futures show leveraged speculators remain bearish on the South African rand.There are other signs metals-linked currencies are getting an extra boost lately. The Canadian and Australian dollars are outperforming many major currencies this year. Meanwhile, the Chilean peso has been one of the best-performing emerging-market currencies versus the greenback of the past year, out of roughly two dozen.Question of TimingAt AGF, which oversees C$40.5 billion ($32 billion), Nakamura says he’s boosted Canadian dollar exposure over the past several months, while remaining overweight the Aussie, on the view that infrastructure spending can only be a tailwind.“One of the tricky things with trying to express opportunities on the infrastructure plan, through currencies, is getting the timing right,” he said. “It can take quite a while to get to procurement, and trying to gauge when you can expect to see the impact on those countries’ economies is quite difficult.”“But one of the appeals of commodities currencies -- whether they’re from the G-10 or large parts of the emerging-market complex -- is that infrastructure creates a level of support for these currencies and countries,” he said.At Brandywine, which manages about $62 billion, McIntyre says he’s grown only more committed to his firm’s holdings of currencies of energy- and metals-producing countries, like Canada and Chile, along with Brazil, Colombia, Indonesia, Norway, New Zealand and Russia, and “is not looking to fade them.”Chile is the world’s biggest producer of copper, which isn’t far from a nine-year high. Australia, another major copper producer, is also a key source of iron ore, the main ingredient in steel. Meanwhile, Canada has both copper and iron ore -- along with nickel.Steel BounceWhen Biden announced his infrastructure plan on March 31, American steel prices jumped almost 6%, with U.S. producers seen as one of the biggest beneficiaries of a deal that passes.Even an infrastructure plan that comes in as low as $600 billion, roughly the amount Republicans offered Thursday, would spur an additional 30% increase in U.S. spending on metals through 2025, according to Chris Plummer, chief executive of metals and mining consulting company Metal Strategies Inc., who cited figures from Dodge Data & Analytics.At Manulife Investment, which managed C$966 billion ($773 billion) as of December, Azzinaro says he has a “favorable” view on the currencies of Canada, Australia, Mexico and New Zealand, and that he’s starting to look into Chile.A senior strategist on global multi-sector fixed income, he says his team has taken positions in those countries’ bonds and is looking to add more, expecting spreads to tighten. His group uses currencies to maximize returns, by either hedging or not hedging against the dollar, and sees all of those countries benefiting from infrastructure spending.“Infrastructure and global reflation are all interconnected, and it’s a global story with a multiyear process that we’ve become a lot more positive on,” Azzinaro said. “And right now, the currency market is connecting all the dots.”(Updates size and scope of Chilean peso in ninth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
(Bloomberg) -- Stocks trimmed their weekly decline after strong economic data added to evidence the recovery is gaining momentum. Traders also assessed a batch of mixed corporate results. The dollar fell.A gauge of output at U.S. manufacturers and service providers reached a record high in April, while a measure of new-home sales rebounded sharply in March to the highest since 2006. Financial, raw-material and tech shares led gains in the S&P 500. Snap Inc. rallied as the social-media company’s user growth beat estimates, while footwear maker Skechers USA surged on an upbeat outlook. Intel Corp., the biggest chipmaker, and American Express Co. sank on disappointing results.There has been a positive note in much of the Purchasing Managers Index data published Friday around the globe. Japan’s manufacturing activity expanded for the third month in a row ahead of much of the country entering a state of emergency. The euro area saw its recovery gain ground with services returning to growth in April and manufacturing expanding at a record pace.Other corporate highlights:Kimberly-Clark Corp., the maker of Scott toilet paper, slid on steep sales declines that signaled the potential end of a boon triggered by the pandemic.Honeywell International Inc. sank as the industrial giant’s midpoint of its full-year profit forecast missed Wall Street’s estimates.Schlumberger, the world’s biggest crude contractor, said it expects a gradual recovery of oil demand to boost overseas work through the end of this year.Equities whipsawed this week, with a flare-up in global coronavirus cases and news that the White House plans to propose almost doubling the capital-gain tax rate for the wealthy added to the volatility. With stocks trading near all-time highs, traders also waded through earnings reports and economic figures to get a sense on the rebound in activity amid a vaccination rollout.“A phrase I have heard a lot over the last couple of weeks is that the market is in a ‘wait and see’ mode,” wrote Chris Iggo, chief investment officer of core investments at AXA Investment Managers. “The consensus is clear, and we are waiting for the data to confirm that the global economy is at the beginning of a long expansion.”Comparing U.S. stocks to high-yield bonds makes equities “look less stretched,” according to Jeroen Blokland, a manager of multi-asset funds at Robeco. While the Cboe Volatility Index, or the VIX, set a 14-month low last week, the yield spread for the Bloomberg Barclays U.S. Corporate High-Yield Index reached its narrowest since July 2007 in the previous week. “Equities are relatively attractive versus high yield” on this basis, he wrote in a blog post.These are some of the main moves in markets:StocksThe S&P 500 rose 0.5% at 10:04 a.m. New York time.The Stoxx Europe 600 Index decreased 0.6%.The MSCI All-Country World Index gained 0.1%.CurrenciesThe Bloomberg Dollar Spot Index fell 0.3%.The euro climbed 0.4% to $1.2068.The Japanese yen appreciated 0.3% to 107.62 per dollar.BondsThe yield on 10-year Treasuries rose one basis point to 1.54%.Germany’s 10-year yield decreased two basis points to -0.27%.Britain’s 10-year yield fell one basis point to 0.729%.CommoditiesWest Texas Intermediate crude fell 0.2% to $61.33 a barrel.Gold rose 0.4% to $1,789.30 an ounce.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
The online personal lender announced on Twitter that it has refiled its S-4 with the Securities and Exchange Commission.
LEO Pharma presents long-term safety and efficacy data for tralokinumab in adults with moderate-to-severe atopic dermatitis at AAD VMX 2021.
The "Pro-green Government Policies and Incentives Power the Electric Bus Market" report has been added to ResearchAndMarkets.com's offering.
The North America swimming pool treatment chemicals for residential application market was valued at US$ 3,938. 74 million in 2019 and is projected to reach US$ 4,896. 87 million by 2027; it is expected to grow at a CAGR of 2.New York, April 23, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "North America Swimming Pool Treatment Chemicals for Residential Application Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product Type" - https://www.reportlinker.com/p06065027/?utm_source=GNW 7% from 2020 to 2027. The rapid growth of the market in this region is attributed to the ever-increasing disposable income of the middle-income group population along with the rising residential construction sector. Additionally, the presence of major market players in the region is also contributing to the market growth. However, the increasing use of natural filtration systems in pools is likely to restrain the market growth.Swimming pool treatment chemicals are used in water treatment processes to eliminate microorganisms of all life stages and sizes.They also keep the water clean and balance the pH level of the water.Some chemicals are used to balance pH levels and offer shock treatment.Swimming pool treatment chemicals are typically manufactured in liquid and powder forms, as well as in concentrates and ready-to-use formulations.The swimming pool treatment chemicals market benefits primarily from the rising popularity of swimming among fitness conscious people as a recreational activity.Additionally, the surge in residential construction and the resultant rise in the number of swimming pools is also fueling the demand for these chemicals.Demand for effective disinfectants such as salts of hypochlorite has escalated significantly since these help remove algae and bacteria from swimming pools. Furthermore, increased consciousness about the quality of pool water, coupled with the strict government regulations and guidelines regarding pool safety, is also fostering the use of swimming pool treatment chemicals.The COVID-19 outbreak has had a brutal impact on the chemicals industry, with the lockdown leading to temporary shutdown of manufacturing facilities and pause of operations.In view of the devastating effects of the SARS-CoV-2 pandemic, players are focusing on bolstering their supply chains while accelerating their manufacturing processes to develop a wider range of swimming pool treatment chemicals, in a bid to prevent further revenue losses.Also, with the construction industry picking up speed following the outbreak, the North America swimming pool treatment chemicals for residential application market is expected to grow in the ensuing period.Based on product type, the North America swimming pool treatment chemicals for residential application market is segmented into sanitizers, balancers, shocks, algaecides, and others. The sanitizers segment held the largest share of the market in 2019, whereas the balancers segment is estimated to register the highest CAGR in the market during the forecast period.A few of the primary and secondary sources associated with this report on the North America swimming pool treatment chemicals for residential application market are the Pool Water Treatment Advisory Group, United States Environmental Protection Agency (EPA), and US Department of Health and Human Services, among others.Read the full report: https://www.reportlinker.com/p06065027/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years Nearly 30 data presentations at AAD and ESPD across clinical and real-world settings, including the impact of Dupixent on disease measures in uncontrolled moderate-to-severe atopic dermatitis Late-breaking Phase 2 data for rilzabrutinib, an investigational therapy for pemphigus vulgaris, a rare, debilitating autoimmune disease, to be presented at AAD PARIS – April 23, 2021 - New analyses from Dupixent® (dupilumab) trials evaluated infection incidence reduction and reinforced the need for no laboratory monitoring in patients six years and older with moderate-to-severe atopic dermatitis. Additional analyses evaluated response rates across a broad population, and the impact of Dupixent on disease extent and severity, quality of life (QoL), and itch. These and other data from real-world settings and clinical trials, including the Dupixent open-label extension (OLE) trials, will be presented at the American Academy of Dermatology (AAD VMX 2021), April 23-25, and at the 20th European Society for Pediatric Dermatology Annual Meeting (ESPD 2021), May 12-14. “The depth and breadth of data being presented at AAD and ESPD support the use of Dupixent in adults, adolescents and children six years and older, addressing multiple critical disease measures such as itch, disease extent and severity, and certain skin infections,” said Naimish Patel, M.D. Head of Global Development in Immunology and Inflammation at Sanofi. “In addition, our expanded efforts in research and development in the immunology space, including rilzabrutinib, underscores our long-term commitment to addressing serious dermatological conditions with unmet patient needs.” Results from a subgroup analysis of the Phase 2 study evaluating rilzabrutinib, an investigational oral Bruton’s tyrosine kinase inhibitor (BTKi), for the treatment of pemphigus vulgaris (PV), include the rates of control of disease activity in patients with moderate-to-severe disease. These data will be presented as a late-breaking abstract oral presentation at AAD VMX 2021. PV is a rare, debilitating autoimmune disease that causes blistering of the skin and mucus membranes. Abstracts to be presented at AAD VMX 2021 Pediatric efficacy and QoL data for Dupixent Abstract 27350: Dupilumab Improves Eczema Area and Severity Index Regional Scores Across All Anatomical Regions in Children Aged 6–11 Years with Severe Atopic Dermatitis (AD), Amy S. PallerAbstract 27375: Dupilumab Provides Early and Sustained Improvement of Sleep Disturbance in Children ≥ 6 Years With Severe Atopic Dermatitis (AD) and Adolescents With Moderate-to-Severe AD, Amy S. PallerAbstract 27389: Rapid and Sustained Improvement in Itch in Children Aged 6–11 Years With Severe Atopic Dermatitis (AD) Treated With Dupilumab: Analysis From the LIBERTY AD PEDS Phase 3 Trial, Amy S. PallerAbstract 27394: Dupilumab Provides Clinically Meaningful Improvement in Atopic Dermatitis (AD) Signs, Symptoms, and Quality of Life in Children With Severe AD: Results From the LIBERTY AD PEDS Phase 3 Clinical Trial, Amy S. PallerAbstract 27406: Dupilumab Improves Signs and Symptoms of Severe Atopic Dermatitis in Children Aged 6–11 Years With and Without Comorbid Asthma, Mark BoguniewiczAbstract 27406: Dupilumab Treatment Improves Health-Related Quality of Life in Children Aged ≥6 to <12 Years With Severe Atopic Dermatitis, Alan Irvine Adult efficacy data for Dupixent Abstract 26839: Dupilumab With Topical Corticosteroids Results in Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across All Anatomic Regions Over 52 Weeks, Andrew BlauveltAbstract 27571: Dupilumab Provides Clinically Meaningful Responses in Adults With Moderate-To-Severe Atopic Dermatitis (AD): Results From LIBERTY AD CHRONOS Study, Jonathan I. Silverberg Long-term data from Dupixent OLE studies, up to three years in adults and up to one year in adolescents (aged 12-17 years) and children (aged 6-11 years) with moderate-to-severe atopic dermatitis. Abstract 26313: Efficacy and Safety of Dupilumab for up to 1 Year in a Phase 3 Open-Label Extension (OLE) Trial (LIBERTY AD PED-OLE) in Adolescents With Uncontrolled, Moderate-To-Severe Atopic Dermatitis (AD), Andrew BlauveltAbstract 26875: 52-Week Laboratory Safety Findings From an Open-Label Extension (OLE) Study of Dupilumab in Adolescent Patients With Atopic Dermatitis (LIBERTY AD PED-OLE), Michael J. CorkAbstract 26880: Long-Term Efficacy and Safety Data for Dupilumab in a Phase 3, Open-Label Extension Trial (LIBERTY AD PED-OLE) in Patients Aged ≥6 to <12 Years With Uncontrolled, Moderate-to-Severe Atopic Dermatitis (AD), Michael J. CorkAbstract 27419: Laboratory Safety of Long-Term Dupilumab Treatment in Adults With Moderate-to-Severe Atopic Dermatitis: Open-Label Extension (OLE) Study, Andrew BlauveltAbstract 27424: Infections in Adults with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Long-Term Data from an Open-Label Extension (OLE) Study, Andrew Blauvelt Real-world data for Dupixent Abstract 27434: Early Trends of Disease Improvement in Adult Patients With Atopic Dermatitis Treated With Dupilumab: Real-World Data From the PROSE Registry, Jerry Bagel Abstracts presenting data on the burden and impact of atopic dermatitis include: Abstract 27430: Worldwide Survey Shows That Atopic Dermatitis Is Associated with a High Disease Burden in Children, Stephan WeidingerAbstract 27473: Worldwide Survey Shows That Atopic Dermatitis in Children is Associated with a Negative Impact on Their Families, Sebastien BarbarotAbstract 28081: Strategies to Improve Quality of Atopic Dermatitis Care in the North America: Results from the Atopic Dermatitis Quality of Care (ADQoC) Initiative, Peter Lio A late-breaking abstract oral presentation for rilzabrutinib: Treatment with Rilzabrutinib Results in Rapid and Significant Decrease in Steroid Use and Improved Quality of Life in Patients with Chronic Relapsing Pemphigus: BELIEVE Phase 2 Study, Dedee F. Murrell Abstracts to be presented at ESPD 2021 Abstracts related to data evaluating efficacy, safety and impact on health-related quality of life of Dupixent include: Efficacy data ESPD21-0326: Dupilumab Provides Clinically Meaningful Improvement in Atopic Dermatitis (AD) Signs, Symptoms, and Quality of Life in Children With Severe AD, Stephan WeidingerESPD21-0330: Dupilumab Improves EASI Regional Scores Across All Anatomical Regions in Children Aged ≥6–<12 Years With Severe Atopic Dermatitis, Michael J. CorkESPD21-0331: Rapid Itch Improvement in Children With Severe Atopic Dermatitis Treated With Dupilumab: A Phase 3 Subset Analysis, Gil YosipovitchESPD21-0332: Dupilumab Significantly Improves Signs and Symptoms of Atopic Dermatitis Assessed by SCORAD in Children Aged ≥6 to <12 Years, Sebastien BarbarotESPD21-0334: Dupilumab Treatment Improves Health-Related Quality of Life in Children Aged ≥6 to <12 Years With Severe Atopic Dermatitis, Alan IrvineESPD21-0340: Dupilumab Improved Itch in Children Aged 6–11 Years With Severe Atopic Dermatitis: Analysis from the LIBERTY AD PEDS Trial, Amy S. PallerESPD21-0341: Dupilumab Treatment Improves Sleep in Children Aged ≥6 to <12 Years With Severe Atopic Dermatitis, Amy S. Paller Long-term data ESPD21-0335: Long-Term Efficacy and Safety of Dupilumab in a Phase 3, Open-Label Extension Trial in Children With Uncontrolled, Moderate-to-Severe Atopic Dermatitis, Michael J. Cork Safety data ESPD21-0200: Increased Incidence of Conjunctivitis With Dupilumab Treatment in Adolescents Appears to be Specific to Atopic Dermatitis, Marjolein De Bruin-WellerESPD21-0308: Laboratory Safety of Dupilumab in Children Aged ≥6–<12 Years With Severe Atopic Dermatitis: Results From a Phase 3 Trial, Andreas Wollenberg Results from a qualitative survey on the impact of atopic dermatitis ESPD21-0322: AD-GAP: A Global, Cross-sectional, Qualitative Survey of Children/Adolescents Aged 6−17 Years With Moderate-to-Severe Atopic Dermatitis, Their Carers, and Physicians, Stephan Weidinger About DupixentDupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. IL-4 and IL-13 are key and central drivers of the type 2 inflammation that plays a major role in atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP) and eosinophilic esophagitis. Dupixent is approved in the U.S. to treat patients aged 6 years and older with moderate-to-severe atopic dermatitis that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies; for use with other asthma medicines for the maintenance treatment of moderate-to-severe eosinophilic or oral steroid dependent asthma in patients aged 12 years and older whose asthma is not controlled with their current asthma medicines; and for use with other medicines for the maintenance treatment of CRSwNP in adults whose disease is not controlled. Outside of the U.S., Dupixent is approved for specific patients with moderate-to-severe atopic dermatitis and certain patients with asthma in a number of other countries around the world, including those in the EU and Japan. Dupixent is also approved in the EU and Japan to treat certain adults with severe CRSwNP. Across all approved indications globally, more than 260,000 patients have been treated with Dupixent. Dupilumab Development ProgramTo date, dupilumab has been studied in more than 10,000 patients across 50 clinical trials in various chronic diseases driven in part by type 2 inflammation. In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven in part by type 2 inflammation or other allergic processes, including pediatric asthma (6 to 11 years of age, Phase 3), chronic obstructive pulmonary disease with evidence of type 2 inflammation (Phase 3), pediatric atopic dermatitis (6 months to 5 years of age, Phase 3), eosinophilic esophagitis (Phase 3), bullous pemphigoid (Phase 3), prurigo nodularis (Phase 3), chronic spontaneous urticaria (Phase 3), chronic inducible urticaria-cold (Phase 3), chronic rhinosinusitis without nasal polyposis (Phase 3), allergic fungal rhinosinusitis (Phase 3) and food allergies (Phase 2). The use of dupilumab in these settings is currently under clinical investigation and its safety and efficacy have not been fully evaluated by any regulatory authority. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. About RilzabrutinibRilzabrutinib is an oral, reversible covalent, Bruton’s tyrosine kinase (BTK) inhibitor being investigated for the treatment of immune mediated diseases. BTK is involved in innate and adaptive immune responses and is a signaling molecule in immune mediated diseases. Rilzabrutinib pre-clinical data demonstrate an ability to help block inflammatory immune cells, eliminate autoantibody destructive signaling, and prevent new autoantibody production without depleting B cells. Rilzabrutinib has the potential to target the underlying disease pathogenesis and has not been shown to alter platelet aggregation. The clinical significance of this data is under investigation. Rilzabrutinib is currently under clinical investigation and its safety and efficacy have not been evaluated by any regulatory authority. Editor’s Note: Rilzabrutinib has been granted orphan drug designation by the FDA for both pemphigus vulgaris (and from the European Commission for the treatment of pemphigus vulgaris and pemphigus foliaceus) and for its investigational use in immune thrombocytopenia (ITP). In November 2020, we announced that rilzabrutinib was granted FDA Fast Track Designation for ITP. About Sanofi Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi, Empowering Life Media Relations ContactsSally Bain Tel.: +1 (781) 264-1091Sally.Bain@sanofi.com Investor Relations - ParisEva Schaefer-JansenArnaud Delepine Investor Relations – North AmericaFelix LauscherFara BerkowitzSuzanne Greco IR main line:Tel.: +33 (0)1 53 77 45 45investor.relations@sanofi.comhttps://www.sanofi.com/en/investors/contact Sanofi Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2020. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. Attachment Press Release
Stock futures pointed to a higher open Friday morning, steadying after selling off sharply on Thursday following a report that President Joe Biden was eyeing a proposal to increase the capital gains tax rate on wealthy individuals.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OTTAWA, April 23, 2021 (GLOBE NEWSWIRE) -- Leonovus Inc. (TSXV:LTV) (the “Company” or “Leonovus”), announces that it has amended certain terms of its public offering, that was previously announced on March 29, 2021 (the “Offering”). Pursuant to the amended terms, the Offering of units of the Company (the “Units”) will be conducted at a price of $0.56 per Unit (the “Offering Price”) for minimum gross proceeds of $2,500,000 and maximum gross proceeds of $4,000,000. Each Unit shall be comprised of one common share of the Company (a “Common Share”) and one Common Share purchase warrant of the Company (a “Warrant”). Each Warrant is exercisable into one Common Share (a “Warrant Share”) at a price of $0.70 for a period of 36 months following completion of the Offering. The Offering is being led by Research Capital Corporation as lead agent and sole bookrunner (the “Lead Agent”), on behalf of a syndicate of agents, including Canaccord Genuity Corp. (collectively with the Lead Agent, the “Agents”). The Company has granted the Agents an option (the “Over-Allotment Option”) to cover over-allotments and for market stabilization purposes, exercisable in whole or in part at the sole discretion of the Agents, at any time up to 30 days from the closing of the Offering, to increase the size of the Offering by up to 15% of the number of Units (and/or the components thereof) sold pursuant to the Offering, on the same terms and conditions of the Offering. The net proceeds raised under the Offering will be used for product development and management, sales and marketing, operating expenses, and general and administrative expenses as well as for working capital requirements and other general corporate purposes. The closing of the Offering is currently expected to be on or about the week of May 3, 2021, or on such date as the Lead Agent and the Company may agree upon, and is subject to certain conditions including, but not limited to the execution of an agency agreement and the receipt of all necessary regulatory approvals including the approval of the TSX Venture Exchange (the “Exchange”). The Company will use commercially reasonable efforts to list the Common Shares, the Warrants and the Warrant Shares on the Exchange, subject to the Company fulfilling all of the listing requirements of the Exchange. The Units are to be sold on a "best efforts" basis through the Agents by way of short form prospectus filed in each of the provinces of Canada (except Québec) and in other jurisdictions outside of Canada and the United States on an exempt basis in accordance with applicable securities laws. The securities described in this press release have not been and will not be registered under the United States Securities Act of 1933, as amended (“U.S. Securities Act”) or any state securities laws. Accordingly, the securities may not be offered or sold in the United States (as such term is defined in Regulation S under the U.S. Securities Act) or to, or for the account or benefit of, a U.S. person (as such term is defined in Regulation S under the U.S. Securities Act) except pursuant to transactions exempt from registration under the U.S. Securities Act and under the securities laws of any applicable state. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of these securities in the United States. Any public offering of securities in the United States must be made by means of a prospectus containing detailed information about the company and management, as well as financial statements. About Leonovus Leonovus is a secure data management software company. The Leonovus suite of data management tools offer an organization what it needs for a complete end-to-end data-centric solution. This solution can stand on its own, or it can easily integrate with the organization's zero-trust strategy and architecture. It takes seamless advantage of the organization's existing storage infrastructure and network architecture, working on-premises, in the cloud, or both. It extends the data-centric controls across the entire architecture, including cloud resources. And it supplies these cybersecurity capabilities for the full lifespan of the data and beyond. The flexible and straightforward solution does not require changes in the method of data use. Applications, services, and users all interact with the data the same way they always have. The system ensures the right users get access to the correct data at the right time, but securely. In addition to working with existing systems, the Leonovus solution aids in the organization's digital transformation by enabling ultramodern data concepts necessary for the data-driven world. These capabilities are included in an automated solution requiring little operations effort and no new skills or expertise needed. The main elements of the Leonovus Unified Smart Data Management suite are: Data Discovery - classification and understanding of your existing data sets.Smart Filer - transparent file-based data controls for cost, flexibility, and scalability.Vault - multi-cloud data management for data lifespan.Data View Gateways - controlled repository internal/external data sharing.Smart Secure Data Lake - a multi-sourced context-rich repository for advanced analytics.Consolidata - multi-sourced data collation and aggregation for near real-time insights.XVault – protocol independent, ultra-secure remote data sharing solution; coming soon. Each is available independently or together as a comprehensive solution set. To learn more, please visit www.leonovus.com. For More Information, please contact:George PretliChief Financial Officer+1.613.319.3540gpretli@leonovus.com Caution regarding forward-looking information This press release contains forward-looking statements and information, which may involve risks and uncertainties, including in relation to pricing and terms of the Offering, receipt of regulatory and Exchange approval of the Offering, the issuance of a receipt for the final short form prospectus, the use of proceeds from the Offering, and the closing of the Offering and timing thereof. The results or events predicted in these statements may differ materially from actual results or events. Factors that might cause a difference include, but are not limited to, competitive developments, risks associated with Leonovus' growth, the state of the financial markets, regulatory risks and other factors. There can be no assurance or guarantees that any statements of forward-looking information contained in this release will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral statements containing forward-looking information are based on the estimates and opinions of management on the dates they are made and expressly qualified in their entirety by this notice. Unless otherwise required by applicable securities laws, Leonovus disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers should not place undue reliance on any statements of forward-looking information that speak only as of the date of this release. Further information on Leonovus' public filings, including its most recent audited consolidated financial statements, are available at www.sedar.com. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
The game’s governing bodies have received a wake-up call to how close they were to disaster
FORM 8.3 IRISH TAKEOVER PANELDISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inWillis Towers Watson plc.Class of relevant security to which the dealings being disclosed relate (Note 2)US$0.000304635 ordinary sharesDate of dealing22nd April 2021 2. INTERESTS AND SHORT POSITIONS (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) LongShort Number(%)Number(%)(1) Relevant securities6,384,201 4.95012% (2) Derivatives (other than options)N/A (3) Options and agreements to purchase/sellN/A Total6,384,201 4.95012% (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) Class of relevant security:LongShort Number(%)Number(%)(1) Relevant securitiesN/A (2) Derivatives (other than options)N/A (3) Options and agreements to purchase/sellN/A TotalN/A 3. DEALINGS (Note 4) (a) Purchases and sales Purchase/saleNumber of relevant securitiesPrice per unit (Note 5)Purchase100234.14Purchase12233.15Purchase50233.15Purchase1,672233.15Purchase290233.15Purchase18233.15Purchase27233.15Purchase332233.15Purchase115233.15Purchase63233.15Sale1,520233.15Sale6,080233.15Sale2,128233.15Sale464233.15Sale3,364233.15Sale45233.15 (b) Derivatives transactions (other than options transactions) Product name, e.g. CFDNature of transaction (Note 6)Number of relevant securities (Note 7)Price per unit (Note 5)N/A (c) Options transactions in respect of existing relevant securities (i) Writing, selling, purchasing or varying Product name, e.g. call optionWriting, selling, purchasing varying etc.Number of securities to which the option relates (Note 7)Exercise priceType, e.g. American, European etc.Expiry dateOption money paid/received per unit (Note 5)N/A (ii) Exercising Product name, e.g. call optionNumber of securitiesExercise price per unit (Note 5)N/A (d) Other dealings (including transactions in respect of new securities) (Note 4) Nature of transaction (Note 8)DetailsPrice per unit (if applicable) (Note 5)N/A 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.N/A Is a Supplemental Form 8 attached? (Note 9)NO Date of disclosure23rd April 2021 Contact nameLionel ColacoTelephone number 020 33956098If a connected EFM, name of offeree/offeror with which connectedN/AIf a connected EFM, state nature of connection (Note 10)N/A
The company faced challenges last year in expanding the label of its only drug. Will 2021 bring different results?
Yahoo Finance